Cash Flow Statement (Annual)

ADBE / Adobe Systems, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss 386,508 774,680 832,847 832,775 289,985 268,395 629,551 1,168,782 1,693,954
  Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization 282,423 292,738 270,205 299,766 321,227 313,590 339,473 331,535 325,997
    Share Based Compensation 167,581 231,086 286,103 298,502 328,987 333,701 335,859 349,912 451,451
    Gain Loss On Sales Of Assets And Asset Impairment Charges - - 0 0 23,151 0 0 - -
    Deferred Income Taxes And Tax Credits 49,590 -172,329 51,415 89,212 29,704 -26,089 -69,657 24,222 51,605
    Gain Loss On Sale Of Properties - - - - 0 0 21,415 0 0
    Unrealized Gain Loss On Investments -11,623 -11,517 4,349 8,535 -5,665 74 9,210 -3,145 5,494
    Gain Loss On Sale Of Property Plant Equipment -821 -674 -14,772 -1,113 -2,759 - - - -
    Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options - - - 16,841 -25,290 -53,225 - - -
    Tax Benefit From Stock Options Exercised1 - - - - - - - - -
    Tax Benefit From Stock Options Exercised 44,381 11,107 9,568 - - - - - -
    Other Noncash Income Expense -2,494 -13,695 -14,992 13,658 -28,185 -1,889 -1,216 -2,022 -4,625
    Taxbenefitfromstockbasedcompensation - - - - 25,290 53,225 68,133 75,102 -
    Excess Tax Benefit From Share Based Compensation Operating Activities 11,980 16,430 9,949 10,003 40,619 53,235 68,153 75,105 0
  Increase Decrease In Operating Capital
    Increase Decrease In Receivables -172,287 134,276 81,065 -45,166 -33,649 -7,928 79,502 160,416 187,173
    Increase Decrease In Prepaid Deferred Expense And Other Assets -21,814 39,963 5,100 -4,552 55,509 1,918 7,701 71,021 -28,040
    Increase Decrease In Accounts Payable -13,601 -10,092 32,203 -62,874 7,132 6,211 22,870 -6,281 -45,186
    Increase Decrease In Accrued Liabilities -52,179 127,814 -24,708 -7,770 41,828 37,544 -5,944 64,978 154,125
    Increase Decrease In Restructuring Reserve -8,446 -26,811 71,932 -66,047 -6,949 8,871 -16,620 - -
    Increase Decrease In Accrued Income Taxes Payable 109,620 -48,656 -16,661 10,041 -58,875 11,006 29,801 -31,987 -34,493
    Increase Decrease In Deferred Revenue -45,142 109,348 101,109 87,340 201,366 326,438 320,801 524,840 475,402
  Net Cash Provided By Used In Operating Activities 1,117,794 1,112,995 1,543,314 1,499,580 1,151,686 1,287,482 1,469,502 2,199,728 2,912,853
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Short Term Investments 1,307,366 2,600,787 1,861,075 1,776,485 2,058,058 2,014,186 2,064,833 2,285,222 1,931,011
  Proceeds From Maturities Prepayments And Calls Of Shortterm Investments 464,031 643,614 486,050 439,878 360,485 272,076 371,790 769,228 759,737
  Proceeds From Sale Of Short Term Investments 1,057,176 1,134,365 1,148,148 1,126,886 1,449,961 1,443,577 1,176,476 860,849 1,393,929
  Payments To Acquire Businesses Net Of Cash Acquired 1,582,669 193,281 259,046 353,195 704,589 29,802 826,004 48,427 459,626
  Payments To Acquire Property Plant And Equipment 119,592 169,642 210,294 271,076 188,358 148,332 184,936 203,805 178,122
  Proceeds From Sale Of Property Plant And Equipment 0 32,151 0 0 24,260 0 57,800 0 0
  Payments To Acquire Longterm Investments 29,143 28,216 65,600 29,701 67,737 17,572 22,779 58,433 29,918
  Proceeds From Sale Of Available For Sale Securities Equity 17,696 22,502 4,558 29,031 6,233 3,532 4,149 5,777 2,134
  Payments For Proceeds From Other Investing Activities -2,771 -2,151 143 - - - - - -
  Net Cash Provided By Used In Investing Activities -1,497,096 -1,159,294 -757,402 -834,662 -1,177,803 -490,707 -1,488,358 -960,033 -442,877
Net Cash Provided By Used In Financing Activities
  Payments For Repurchase Of Common Stock 350,013 850,020 695,015 405,000 1,100,000 600,000 625,000 1,075,000 1,100,000
  Proceeds From Sale Of Treasury Stock 179,566 139,270 144,754 169,274 500,776 227,841 164,270 145,697 158,351
  Excess Tax Benefit From Share Based Compensation Financing Activities 11,980 16,430 9,949 10,003 40,619 53,235 68,153 75,105 0
  Cost Of Issuance Of Treasury Stock - - - 65,977 97,418 173,675 186,373 236,400 240,126
  Proceeds From Long Term Debt And Long Term Capital Lease Obligations - 1,493,439 0 3,152 25,703 0 989,280 - -
  Proceeds From Issuance Of Senior Long Term Debt 650,000 1,493,439 0 - - - - - -
  Proceeds From Issuance Of Long Term Debt - - - - - 0 989,280 0 -
  Repayments Of Long Term Debt And Capital Securities 0 1,003,719 10,046 9,855 25,879 14,684 602,189 108 1,960
  Proceeds From Issuance Of Debt - - - - - - 989,280 0 0
  Repayments Of Acquired Debt 13,897 0 0 - - - - - -
  Payments Of Debt Issuance Costs 0 10,662 0 2,297 357 0 8,828 0 0
  Net Cash Provided By Used In Financing Activities 477,636 -215,262 -550,358 -234,723 -559,138 -507,283 -200,687 -1,090,706 -1,183,735
Effect Of Exchange Rate On Cash And Cash Equivalents 14,703 11,965 4,055 5,357 -5,241 -6,648 -21,297 -14,234 8,516
Cash And Cash Equivalents Period Increase Decrease 113,037 -249,596 239,609 435,552 -590,496 282,844 -240,840 134,755 1,294,757
Cash And Cash Equivalents At Carrying Value - - 989,500 1,425,052 834,556 1,117,400 876,560 1,011,315 2,306,072
Supplemental Cash Flow Information
  Income Taxes Paid Net 105,158 389,114 158,373 201,125 129,701 20,140 203,010 249,884 396,668
  Interest Paid Net 2,088 34,632 63,967 66,265 64,843 68,886 56,014 66,193 69,430
Noncash Investing And Financing Items
  Equity Awards Assumed For Acquisition 84,968 3,264 0 4,265 1,160 21 677 0 10,348
  Investmentin Lease Receivable Appliedto Building Purchase - - - 0 0 126,800 0 0 80,439
  Capital Lease Obligations Incurred 0 32,151 0 0 25,700 - - - -

Peers - Prepackaged Software (7372)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

15h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

16h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 00724F101